A6733

Auranofin

≥98% (HPLC)

• Sinónimos: 3,4,5-Triacetyloxy-6-(acetyloxymethyl) oxane-2-thiolate triethylphosphanium, 1-Thio-β-D-glucopyranosatotriethylphosphine gold-2,3,4,6-tetraacetate, SKF 39162
• Empirical Formula (Hill Notation): C₂₀H₃₄AuO₉PS
• Peso molecular: 678.48
• Número de EC: 251-801-9
• Número MDL: MFCD00080759
• ID de la sustancia en PubChem: 329770903
• NACRES: NA.77

Propiedades

• Nivel de calidad: 100
• ensayo: ≥98% (HPLC)
• formulario: powder
• solubilidad: DMSO: ≥5 mg/mL
• emisor: Prometheus
• temp. de almacenamiento: room temp
• SMILES string: CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O
• InChI: 1S/C14H20O9S.C6H15P.Au/c1-6(15)19-5-10-11(20-7(2)16)12(21-8(3)17)13(14(24)23-10)22-9(4)18;1-4-7(5-2)6-3;/h10-14,24H,5H2,1-4H3;4-6H2,1-3H3;/q;;+1/p-1/t10-,11-,12+,13-,14+;;/m1../s1
• InChI key: AUJRCFUBUPVWSZ-XTZHGVARSA-M

Descripción

Aplicación

Auranofin inhibits both leukocyte activation pathways at multiple sites and the release of inflammatory mediators from human macrophages, basophils, and pulmonary mast cells. Auranofin also inhibits 5-lipoxygenase in human neutrophils, IKB kinase (IKK) by modifying Cys-179 of the IKKβ subunit 5 and selenoenzyme thioredoxin reductase (TrxR) which is involved in the defense against oxidative stress. Auranofin is a disease-modifying antirheumatic drug (DMARD) and has been used to study the anti-proliferative effects against OVCAR-3 human ovarian carcinoma cells.

Envase

10, 50 mg in glass bottle

Acciones bioquímicas o fisiológicas

Auranofin inhibits various leukocyte activation pathways at multiple sites. Auranofin inhibits the release of inflammatory mediators from human macrophages, basophils, and pulmonary mast cells. The compound also inhibits 5-lipoxygenase in human neutrophils. Auranofin is a disease-modifying antirheumatic drug (DMARD). The compound is a potent inhibitor of selenoenzyme thioredoxin reductase (TrxR), which is involved in defense against oxidative stress. Auranofin is an efficient inducer of mitochondrial membrane permeability transition pore in the presence of calcium ions related to its inhibition of mitochondrial thioredoxin reductase. Auranofin inhibits IKB kinase (IKK) by modifying Cys-179 of the IKKβ subunit 5.

Características y beneficios

This compound was developed by Prometheus. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Información de seguridad

• pictogramas: GHS06,GHS08
• Palabra de señalización: Danger
• Frases de peligro: H301 - H361
• Consejos de prudencia: P201 - P202 - P264 - P270 - P280 - P301 + P310
• Clasificaciones de peligro: Acute Tox. 3 Oral - Repr. 2
• Código de clase de almacenamiento: 6.1C - Combustible, acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• WGK: WGK 3
• Punto de inflamabilidad F: Not applicable
• Punto de inflamabilidad C: Not applicable
• Equipo de protección personal: dust mask type N95 (US), Eyeshields, Faceshields, Gloves